ZP2

Across TCGA pan-cancer cohorts, ZP2 RNA is linked to patient survival in 18 of 34 cancer types, making it the most broadly survival-associated ZP2 data layer compared with 7 for mutation status.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher ZP2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZP2 expression acts as an unfavorable survival marker, although some lineages such as READ and PRAD show a favorable association.

DLBC, SKCM, and MESO are the cancer types where ZP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Tertile	II,III,IV	0.447	1.000	.003	45	view →
SKCM	OS	Tertile	All	0.697	0.821	.001	35	view →
MESO	OS	Tertile	All	0.200	0.605	.003	33	view →
LUSC	OS	Tertile	IV	0.057	0.786	.017	27	view →
LIHC	DFS	Tertile	All	0.177	0.462	.001	24	view →
READ	DFS	Median	IV	0.787	0.401	.011	20	view →
PRAD	DFS	Median	All	0.863	0.656	.006	18	view →
HNSC	OS	Median	II,III,IV	0.801	0.705	.009	16	view →
KICH	DFS	Median	II,III,IV	0.422	0.937	.004	14	view →
PAAD	OS	Quartile	All	0.505	0.284	.021	13	view →
STAD	OS	Tertile	III,IV	0.424	0.602	.020	9	view →
GBM	DFS	Tertile	All	0.348	0.216	.042	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 18 lineages.

ZP2–DLBC (DFS)

Open the DLBC breakdown →